Total number of shares and voting rights in Zealand Pharma at March 31, 2024

Udgivet den 31-03-2024  |  kl. 15:00  |  

Company announcement - No. 21 / 2024

Total number of shares and voting rights in Zealand Pharma at March 31, 2024

Copenhagen, Denmark, March 31, 2024 - Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. 

In Company announcement No. 11/2024 from March 5, 2024, and in company announcement No. 19/2024, from March 26,2024, Zealand announced an increase in share capital relating to exercise of employee warrants. Following these announcements, the table below lists the total number of shares and voting rights in Zealand up to and including March 31, 2024.

 

Date
Number of shares
(nominal value of DKK 1 each)
Share capital
(nominal value in DKK)
Number of voting rights
March 31, 2024 62,648,011 62,648,011 62,648,011


# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) (Zealand) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand's business and activities, please visit www.zealandpharma.com.

Contact:

Adam Lange
Investor Relations Officer
Zealand Pharma
Email: akl@zealandpharma.com
 
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com


\Hugin

Udgivet af: NPinvestordk

Seneste nyheder

11:59 Freetrailers toplinje vokser pænt i andet kvartal - bundlinjen følger med
11:45 Aktier/middag: ISS og Zealand tager top og bund efter årsregnskaber i grønt marked
11:28 Ledelse og markedet er enig: Flot kvartalsregnskab fra FLSmidth
11:06 MT Højgaard/CEO: Robust år i et marked tynget af geopolitik og renteusikkerheder
11:01 ISS-chef ser ingen grund til store opkøb i 2025 - tysk joker kan løfte tilbagekøbsprogram
10:28 DAB leverer historisk overskud i 2024: Strategiskift vil påvirke i fremtiden
10:15 NNIT har vasket tavlen ren i 2025: Danske Bank er positiv men sænker kursmål
10:01 Sydbank får løftet kursmålet hos Danske Bank: Ser mulighed for købstilbud
09:55 Nilfisk-topchef håber på trendskifte på vanskeligt amerikansk marked
09:42 Cbrain vil stille skarpt på udlandet: Ændrede vækstambitioner straffes på børsen
09:28 FLSmidths finansdirektør ser fordele ved Trump - både for Mining og Cement
09:13 Aktier/åbning: ISS og Zealand tager top og bund efter regnskab i grønt eliteindeks
09:12 Zealand Pharma sætter op mod 2,5 mia. kr. af til driften i 2025
08:53 Zealand Pharma har speederen i bund: Nye studier følger år med "fantastiske data"
08:35 Obligationer/åbning: Marginalt rentefald i den tidlige handel
08:34 ISS overrasker markedet med stort tilbagekøbsprogram
08:33 Aktier/tendens: ISS, Nilfisk og FLSmidth i fokus efter regnskaber
08:14 KORR: Airbus skuffer en smule med udsigten til flyleveringer i 2025
08:12 Zealand-topchef ser større sandsynlighed for partnerskab med selskabets kronjuvel i 2025 end ikke
07:40 FLSmidth leverer opløftende prognose for 2025